insights_auto
Why is DUL down २.२४%?
Dive Deeperchevron_right
DUL:ETR
Alnylam Pharmaceuticals, Inc.
€ २००.९०
arrow_downward
-२.२४%(-४.६०) 1D
अक्टोबर १३, १७:३५:५२ GMT+२ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DUL...
Open
€ २०२.६०
High
€ २०२.६०
Low
€ २००.९०
Mkt. cap
२९.९५ अरब
Avg. vol.
३९.००
Volume
०.००
52-wk high
€ ४१७.४०
52-wk low
€ १७७.१०
No. of employees
२ हजार
Open
€ २०२.६०
High
€ २०२.६०
Low
€ २००.९०
Mkt. cap
२९.९५ अरब
Avg. vol.
३९.००
Volume
०.००
52-wk high
€ ४१७.४०
52-wk low
€ १७७.१०
No. of employees
२ हजार
News stories
From web sources and news partners
Investing.com Canada
·
१२ घण्टा पहिले
Form 4 Alnylam Pharmaceuticals Inc For: 13 October By Investing.com
Investing.com
·
२ दिन पहिले
Alnylam EVP Bryan Supran sells $398,855 in shares
Simply Wall Street
·
२ दिन पहिले
How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors
The Globe and Mail
·
२ हप्ता पहिले
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.